首页> 外文期刊>European urology >Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections.
【24h】

Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections.

机译:神经源性逼尿肌过度活动的患者注射肉毒杆菌毒素逼尿肌可显着降低症状性尿路感染的发生率。

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVES: To study the effect of botulinum toxin A (BoNTA) injections into the detrusor muscle on the incidence of symptomatic urinary infections in patients with neurogenic detrusor overactivity. METHODS: Between February 2004 and June 2005, 30 patients (18 men, 12 women), mean age 39.4+/-12.1 yr, with neurogenic detrusor overactivity received an injection of 300 U Botox (Allergan Inc., Irvine, CA, USA) into the detrusor. Fifteen patients had multiple sclerosis, 14 had spinal cord injury, and 1 had myelitis. Twenty-two patients had urinary incontinence. Patients were either resistant to anticholinergic medications, had discontinued treatment because of adverse effects, or had contraindications to anticholinergic drugs. Before and 6 wk after injection, each patient kept a bladder diary and underwent urodynamic investigation, retrograde and voiding cystourethrography, and urine culture. All symptomatic urinary infections (pyelonephritis, orchitis, prostatitis) occurring in the 6 mo before and the 6 moafter injection were recorded. RESULTS: Before injection, the mean number of symptomatic urinary infections over 6 mo was 1.75+/-1.87. After injection, the mean was 0.2+/-0.41 (p=0.003), and only 3 patients presented symptomatic urinary infections. These patients were those who showed less improvement in their urodynamic parameters after injection (volume of the first uninhibited contraction, maximum bladder pressure, and maximum cystometric capacity, respectively; p=0.0037, p=0.0002, p=0.0027, ANOVA). CONCLUSIONS: BoNTA injections into the detrusor muscle significantly decreased the incidence of symptomatic urinary infections. This effect seems to be related to improvement in urodynamic parameters, reflecting improved reservoir capacity at low pressure.
机译:目的:研究肉毒毒素A(BoNTA)注射到逼尿肌中对神经源性逼尿肌功能亢进患者症状性尿路感染的发生率的影响。方法:2004年2月至2005年6月,对30例平均年龄39.4 +/- 12.1岁,神经原性逼尿肌过度活动的患者(平均年龄39.4 +/- 12.1岁)注射了300 U肉毒杆菌毒素(美国加利福尼亚州尔湾市的Allergan Inc.)进入逼尿肌。 15例患有多发性硬化症,14例患有脊髓损伤,1例患有脊髓炎。 22名患者出现尿失禁。患者要么对抗胆碱能药物耐药,要么因不良反应而中止治疗,或者对抗胆碱能药物有禁忌症。注射前和注射后6周,每位患者保留膀胱日记,并进行尿流动力学检查,逆行和排尿膀胱尿道造影以及尿培养。记录在注射前6个月和注射后6个月内发生的所有症状性尿路感染(肾盂肾炎,睾丸炎,前列腺炎)。结果:注射前6个月以上症状性尿路感染的平均数为1.75 +/- 1.87。注射后,平均值为0.2 +/- 0.41(p = 0.003),只有3例出现症状性尿路感染。这些患者是那些注射后尿动力学参数改善较小的患者(首次未抑制收缩的体积,最大膀胱压力和最大膀胱测压能力; p = 0.0037,p = 0.0002,p = 0.0027,ANOVA)。结论:向逼尿肌注射BoNTA可显着降低症状性尿路感染的发生率。这种作用似乎与尿动力参数的改善有关,反映了低压下储层容量的提高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号